heart transplant patients" (J. W. Rossano, S. W. Denfield, E. O. Smith,
et al.) -- oral presentation, 10:45 a.m. - 12:45 p.m. (Oral Session:
The Long and the Short of Pediatric Immunosuppression and Immunology)
-- "Low Cylex immune response associated with increased infection in
pediatric heart transplants" (A. P. Barnes, S. M. Daneman, K. J.
Guleserian, et al.) -- poster presentation, 5:45 p.m. - 6:45 p.m.
(General Posters: Poster Session III)
-- "Monitoring for PTLD in children after lung transplantation"
(O. Elidemir, B. S. Kancheria, M. G. Schecter, et al.) -- poster
presentation, 5:45 p.m. - 6:45 p.m. (General Posters: Poster
The various studies report on the clinical use of the ImmuKnow immune function assay in adult and in pediatric patients. The use of the ImmuKnow assay for identification of patients as described in some of these studies has not been cleared by the U.S. Food & Drug Administration (FDA). The company may use data from these or similar studies to support future FDA marketing applications.
ImmuKnow is an immune cell function assay that can detect cell-mediated immunity (CMI) in adult immunosuppressed patients by measuring the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation.
The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of ImmuKnow assays should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. The use of the ImmuKnow assay as described in these studies has not been cleared by the FDA. The company may use data from these or similar studies to support a future FDA marketing application for a similar indication.
ImmuKnow is a product of Cylex(TM),
|SOURCE Cylex Inc.|
Copyright©2008 PR Newswire.
All rights reserved